Dr.  Jallouk’s ASCO update showed that in TP53‑mutated CLL, zanubrutinib delivered five‑year PFS of 72 % and OS of 85.1 % in SEQUOIA, with zanubrutinib + venetoclax achieving even deeper, MRD‑negative responses. He also reported STARGLO’s significant PFS/OS gains for the glofitamab‑GemOx regimen in large B‑cell lymphoma, although the FDA’s ODAC voted against approval because of pronounced geographic heterogeneity, notably in U.S. patients.